VBI Vaccines (NASDAQ:VBIV) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

VBI Vaccines (NASDAQ:VBIV) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02), Fidelity Earnings reports. The firm had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.90 million. VBI Vaccines had a negative net margin of 1,582.45% and a negative return on equity of 73.80%.

Shares of VBIV opened at $0.55 on Friday. The company’s fifty day moving average is $0.54 and its two-hundred day moving average is $1.04. The stock has a market capitalization of $106.76 million, a P/E ratio of -0.57 and a beta of 0.52. VBI Vaccines has a 1 year low of $0.47 and a 1 year high of $2.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.92 and a current ratio of 0.95.

In other news, CEO Jeff Baxter bought 150,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were purchased at an average cost of $0.50 per share, with a total value of $75,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 608,255 shares in the company, valued at $304,127.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Perceptive Advisors Llc bought 20,000,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were purchased at an average cost of $0.50 per share, for a total transaction of $10,000,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 30,212,000 shares of company stock worth $15,105,440. 10.50% of the stock is owned by corporate insiders.

VBIV has been the topic of several recent research reports. ValuEngine raised shares of VBI Vaccines from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research cut shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Further Reading: What is an investor looking for in an SEC filing?

Earnings History for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.